Jenner & Block

Louis Fogel Summarizes “Key Developments in Biosimilar Litigation"

In this video interview, Jenner & Block Partner Louis E. Fogel discusses highlights from the firm’s recent webinar “Key Developments in Biosimilar Litigation.” 

The video (4:53) covers the following topics:

  • The market for biosimilars;
  • The Biologics Price Competition and Innovation Act (BPCIA); and
  • Three key cases interpreting the Act -- Sandoz v. Amgen (Enbrel), Amgen v. Sandoz (Neupogen) and Janssen Biotech v. Celltrion.

The video interview is drawn from a recent webinar that Dr. Fogel co-presented with Partners Paul D. Margolis and Steven R. Trybus.

The webinar is available for viewing here.  (Registration is required.)

Dr. Fogel counsels life sciences clients in all aspects of complex patent litigation to help businesses achieve their strategic goals. He has litigated across a range of technologies, including biotechnology, pharmaceuticals, medical devices and consumer electronics. He is also an experienced trial lawyer with courtroom experience before both juries and in bench proceedings.